Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/08/26	SEK 13.20	+2.33%	571
17/08/26	SEK 12.90	+2.79%	17,165
14/08/26	SEK 12.55	0.00%	7,665
13/08/26	SEK 12.55	-1.95%	20,023
12/08/26	SEK 12.80	-1.54%	3,110

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 11:43:43 18/08/2026 +04			5-day change	1st Jan Change
13.20 ^SEK	+2.33%		+1.54%	-33.33%

07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW

Market Cap	91.06M 9.59M 8.28M 7.77M 7.08M 13.3M 917M 13.49M 35.68M 459M 36.01M 35.23M 1.53B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	91.06M 9.59M 8.28M 7.77M 7.08M 13.3M 917M 13.49M 35.68M 459M 36.01M 35.23M 1.53B	EV / Sales 2026 *	1.2x	EV / Sales 2027 *	-
Free-Float	42.81%	Yield 2026 *	-	Yield 2027 *	-

07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Annexin Pharmaceuticals AB Provides Update on ANXV Clinical Study in Retinal Vein Occlusion and Diabetic Retinopathy	CI
04-13	Annexin Pharmaceuticals Mulls SEK20 Million Rights Issue; Bridge Facility Secured	MT
04-13	Annexin secures financing through bridge loan facility, plans rights issue	RE

07-21	Annexin updates on nine patients treated in NEXUS study	AQ
07-03	Annexin's rights issue 98 percent subscribed	AQ
06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ
06-15	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
06-10	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news : Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Course Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	+2.33%
1 week	+1.54%
Current month	+7.76%
1 month	+8.20%
3 months	-11.41%
6 months	-41.07%
Current year	-33.33%

1 week	12.4	13.3
1 month	11.45	13.3
Current year	11.05	23.6
1 year	11.05	30
3 years	11.05	97.6
5 years	11.05	225
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	+2.33%	+1.54%	-54.79%	-83.78%	9.59M
WUXI APPTEC CO., LTD.	+4.80%	+3.44%	+70.64%	+109.32%	73.25B
ARGENX SE	-0.94%	+13.06%	+47.68%	+88.72%	61.95B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	28.02B
WUXI BIOLOGICS (CAYMAN) INC.	+5.33%	+5.74%	+56.84%	+21.40%	24.15B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.01B
PHARMAESSENTIA CORPORATION	-6.00%	+6.02%	+244.39%	+430.80%	18.35B
GENMAB A/S	+1.21%	+6.57%	+40.90%	-13.48%	19.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.73%	+2.46%	+21.20%	+556.36%	15.92B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.96B
Average	+1.47%	+1.49%	+44.45%	+172.35%	27.71B
Weighted average by Cap.	+1.76%	+3.14%	+54.71%	+164.49%

	2026 *	2027 *
Net sales	75.6M 7.96M 6.87M 6.45M 5.87M 11.04M 761M 11.2M 29.63M 381M 29.89M 29.25M 1.27B	-
Net income	19.6M 2.06M 1.78M 1.67M 1.52M 2.86M 197M 2.9M 7.68M 98.89M 7.75M 7.58M 329M	-58M -6.11M -5.27M -4.95M -4.51M -8.47M -584M -8.59M -22.73M -293M -22.94M -22.44M -973M
Net Debt	-	-